HLB Cell, a subsidy of HLB Life Science, succeeded in producing an extracellular matrix that is rich in human basement membrane through a normal cell culture procedure, the cell therapy drug developer said Wednesday.

The company said it will release the organoid biomaterial called Hutrigel, which is based on normal human cells, in the second quarter of the year. 

Please refer to the following website for further details:   

https://www.koreatimes.co.kr/www/nation/2023/04/779_348477.html?utm_source=na